Streetbeat News

CYTH

Cyclo Therapeutics, Inc.

https://www.cyclotherapeutics.com

Industry

Drug Manufacturers - Specialty & Generic

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Ascendiant Capital has maintained a Buy rating on Cyclo Therapeutics but lowered the price target from $2.6 to $0.95, indicating a more cautious outlook.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 10:10 am

HC Wainwright & Co. has downgraded Cyclo Therapeutics from Buy to Neutral and reduced the price target from $3 to $0.95, indicating a less optimistic outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 11:23 am

U.S. stocks fell with the Nasdaq down over 1%. Williams-Sonoma shares dropped 8% after Q2 results, despite beating EPS expectations. Peloton shares surged 37% on strong results. Air Industries Group shares soared 106% after securing a $110 million contract.

Portfolio Pulse from Avi Kapoor

August 22, 2024 | 6:47 pm

U.S. stocks fell as initial jobless claims rose slightly more than expected. Peloton, Rezolve AI, and Air Industries saw significant stock gains due to positive news, while Revelation Biosciences, Cyclo Therapeutics, and Oblong experienced sharp declines.

Portfolio Pulse from Avi Kapoor

August 22, 2024 | 4:16 pm

U.S. stocks rose with the Dow gaining over 100 points. BJ's Wholesale Club reported strong earnings, beating estimates. Several stocks saw significant price movements, including Staffing 360 Solutions, SRIVARU Holding, and Air Industries Group, which surged, while Revelation Biosciences, Cyclo Therapeutics, and Oblong fell.

Portfolio Pulse from Avi Kapoor

August 22, 2024 | 1:54 pm

Cyclo Therapeutics shares declined following the announcement of a merger agreement with Rafael Holdings.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 12:33 pm

Rafael Holdings and Cyclo Therapeutics have agreed to merge, focusing on Trappsol Cyclo for Niemann-Pick Disease Type C1. Rafael will issue Class B shares to Cyclo's shareholders, valuing Cyclo shares at $0.95 each.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 10:52 am

HC Wainwright & Co. has reiterated its Buy rating on Cyclo Therapeutics (NASDAQ:CYTH) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 4:12 pm

Cyclo Therapeutics (NASDAQ:CYTH) reported Q2 earnings per share (EPS) of $(0.21), missing the analyst estimate of $(0.16) by 31.25%. Sales were $123.10K, missing the estimate of $267.50K by 53.98%. Despite the misses, EPS improved by 36.36% and sales increased by 5.11% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:03 pm

Cyclo Therapeutics has received a grant notice from the European Patent Office for a patent on methods for treating Alzheimer's Disease. The European Patent Number 3873604B will be published on August 21, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.